Researchers at SfN 2016 painted a more detailed picture of how misfolded proteins may proliferate, as one cell spreads these “hot potatoes” to the next.
Despite no warning signs in ongoing clinical trials, researchers are searching for safer drugs, and better biomarkers to measure what they do.
In Seeon, researchers reported that blocking the protease may heal dystrophic neurites and repair electrical activity.
At the 2nd Kloster Seeon meeting on BACE proteases, researchers linked BACE substrates to regulation of synaptic activity.
Researchers at the Kloster Seeon meeting pressed in on the question of what are the physiological functions of this protease after development is complete.
Despite concerns over potential side effects, researchers seem more enthusiastic than ever about the prospect of treating Alzheimer’s with β-secretase inhibitors.
Sometimes challenged, the idea that pathogenic proteins spread through the brain got a lift from new animal model data presented at the frontotemporal dementia meeting.
Geneticists at frontotemporal dementia conference reported a new link with a ubiquitine enzyme and strengthened other gene associations.
Several such tests generated enthusiasm at the international frontotemporal dementia congress.
Researchers at an international frontotemporal dementia congress reported progress in finding markers that track disease, but no luck thus far with diagnostic markers.
Researchers reported negative findings from three trials at ICFTD 2016.
With a laser focus on biomarkers and disease mechanisms, researchers at the 10th ICFTD meeting prepared the ground for therapeutic studies.
Read our full coverage of this year’s AAIC conference.
Increasingly, people must learn of their amyloid status and/or ApoE genotype in order to enter secondary prevention trials. At AAIC, researchers laid out their procedures to ethically break the news.
Different genetic factors underlie amyloid accumulation and atrophy, researchers at AAIC reported.